当前位置: 首页 >> 检索结果
共有 1921 条符合本次的查询结果, 用时 3.1747309 秒

1301. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.

作者: Thomas X Lu.;Matthew Dapas.;Erika Lin.;Trevor Peters.;Atsushi Sakuraba.
来源: Gut. 2021年70卷11期2076-2084页
In treating patients with inflammatory bowel disease (IBD), how concomitant medications influence the response to infliximab is largely unexplored. We aim to evaluate whether proton pump inhibitors (PPIs) affect the response to infliximab therapy in patients with IBD.

1302. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma.

作者: Dapeng Hao.;Siyuan He.;Kazuto Harada.;Melissa Pool Pizzi.;Yang Lu.;Pujun Guan.;Lu Chen.;Ruiping Wang.;Shaojun Zhang.;Matheus Sewastjanow-Silva.;Ahmed Abdelhakeem.;Namita Shanbhag.;Manoop Bhutani.;Guangchun Han.;Jeffrey H Lee.;Shuangtao Zhao.;Brian Weston.;Mariela Blum Murphy.;Rebecca Waters.;Jeannelyn Santiano Estrella.;Sinchita Roy-Chowdhuri.;Qiong Gan.;Ju-Seog Lee.;Guang Peng.;Samir M Hanash.;George Adrian Calin.;Xingzhi Song.;Jianhua Zhang.;Shumei Song.;Linghua Wang.;Jaffer A Ajani.
来源: Gut. 2021年70卷11期2055-2065页
Prognosis of patients with advanced oesophagogastric adenocarcinoma (mEGAC) is poor and molecular determinants of shorter or longer overall survivors are lacking. Our objective was to identify molecular features and develop a prognostic model by profiling the genomic features of patients with mEGAC with widely varying outcomes.

1303. Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis.

作者: Andrea C Masi.;Nicholas D Embleton.;Christopher A Lamb.;Gregory Young.;Claire L Granger.;Julia Najera.;Daniel P Smith.;Kristi L Hoffman.;Joseph F Petrosino.;Lars Bode.;Janet E Berrington.;Christopher J Stewart.
来源: Gut. 2021年70卷12期2273-2282页
Necrotising enterocolitis (NEC) is a devastating intestinal disease primarily affecting preterm infants. The underlying mechanisms are poorly understood: mother's own breast milk (MOM) is protective, possibly relating to human milk oligosaccharide (HMO) and infant gut microbiome interplay. We investigated the interaction between HMO profiles and infant gut microbiome development and its association with NEC.

1304. Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies.

作者: Dorothea Bankwitz.;Akash Bahai.;Maurice Labuhn.;Mandy Doepke.;Corinne Ginkel.;Tanvi Khera.;Daniel Todt.;Luisa J Ströh.;Leona Dold.;Florian Klein.;Frank Klawonn.;Thomas Krey.;Patrick Behrendt.;Markus Cornberg.;Alice C McHardy.;Thomas Pietschmann.
来源: Gut. 2021年70卷9期1734-1745页
Neutralising antibodies are key effectors of infection-induced and vaccine-induced immunity. Quantification of antibodies' breadth and potency is critical for understanding the mechanisms of protection and for prioritisation of vaccines. Here, we used a unique collection of human specimens and HCV strains to develop HCV reference viruses for quantification of neutralising antibodies, and to investigate viral functional diversity.

1305. Far reach of Fusobacterium nucleatum in cancer metastasis.

作者: Ye Yang.;Christian Jobin.
来源: Gut. 2020年

1306. F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer.

作者: Jie Hong.;Fangfang Guo.;Shi-Yuan Lu.;Chaoqin Shen.;Dan Ma.;Xinyu Zhang.;Yile Xie.;Tingting Yan.;TaChung Yu.;Tiantian Sun.;Yun Qian.;Ming Zhong.;Jinxian Chen.;Yanshen Peng.;Cheng Wang.;Xiang Zhou.;Jianjun Liu.;Qiang Liu.;Xiong Ma.;Ying-Xuan Chen.;Haoyan Chen.;Jing-Yuan Fang.
来源: Gut. 2021年70卷11期2123-2137页
Microbiota disorder promotes chronic inflammation and carcinogenesis. High glycolysis is associated with poor prognosis in patients with colorectal cancer (CRC). However, the potential correlation between the gut microbiota and glucose metabolism is unknown in CRC.

1307. Clinical, financial and academic implications of COVID-19 on a tertiary care interventional endoscopy programme.

作者: Ji Young Bang.;Robert Hawes.;Shyam Varadarajulu.
来源: Gut. 2020年

1308. Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.

作者: Xiaolong He.;Jie Gao.;Liang Peng.;Tongtong Hu.;Yu Wan.;Meijuan Zhou.;Peilin Zhen.;Hong Cao.
来源: Gut. 2021年70卷10期1872-1883页
O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation. Gut microbiota encode various enzymes involved in O-GlcNAcylation. However, the characteristics, abundance and function of these enzymes are unknown.

1309. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).

作者: Ming-Lung Yu.;Chung-Feng Huang.;Yu-Ju Wei.;Wen-Yi Lin.;Yi-Hung Lin.;Po-Yao Hsu.;Cheng-Ting Hsu.;Ta Wei Liu.;Jia-Jung Lee.;Sheng-Wen Niu.;Jiun-Chi Huang.;Tzu-Sui Hung.;Ming-Lun Yeh.;Ching-I Huang.;Po-Cheng Liang.;Ming-Yen Hsieh.;Szu-Chia Chen.;Jee-Fu Huang.;Jer-Ming Chang.;Yi-Wen Chiu.;Chia-Yen Dai.;Shang-Jyh Hwang.;Wan-Long Chuang.; .
来源: Gut. 2021年70卷12期2349-2358页
HCV prevails in uremic haemodialysis patients. The current study aimed to achieve HCV microelimination in haemodialysis centres through a comprehensive outreach programme.

1310. Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort.

作者: Seung Won Lee.;Jee Myung Yang.;In Kyung Yoo.;Sung Yong Moon.;Eun Kyo Ha.;Abdullah Özgür Yeniova.;Joo Young Cho.;Min Seo Kim.;Jae Il Shin.;Dong Keon Yon.
来源: Gut. 2021年70卷10期2013-2015页

1311. Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.

作者: Shushu Song.;Yinghong Shi.;Weicheng Wu.;Hao Wu.;Lei Chang.;Peike Peng.;Lei Zhang.;Jia Fan.;Jianxin Gu.;Yuanyuan Ruan.
来源: Gut. 2021年70卷11期2159-2171页
Dysfunction of endoplasmic reticulum (ER) proteins is closely related to homeostasis disturbance and malignant transformation of hepatocellular carcinoma (HCC). Reticulons (RTN) are a family of ER-resident proteins critical for maintaining ER function. Nevertheless, the precise roles of RTN in HCC remain largely unclear. The aim of the study is to examine the effect of reticulon family member RTN3 on HCC development and explore the underlying mechanisms.

1312. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.

作者: Alessandro Mantovani.;Graziana Petracca.;Giorgia Beatrice.;Alessandro Csermely.;Amedeo Lonardo.;Jörn M Schattenberg.;Herbert Tilg.;Christopher D Byrne.;Giovanni Targher.
来源: Gut. 2022年71卷1期156-162页
Studies reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased risk of chronic kidney disease (CKD). However, whether this risk changes with increasing severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CKD.

1313. Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy.

作者: Craig Haifer.;Aiasha Saikal.;Ramesh Paramsothy.;Nadeem O Kaakoush.;Rupert W Leong.;Thomas J Borody.;Michael A Kamm.;Sudarshan Paramsothy.
来源: Gut. 2021年70卷11期2210-2211页

1314. Iqgap3-Ras axis drives stem cell proliferation in the stomach corpus during homoeostasis and repair.

作者: Junichi Matsuo.;Daisuke Douchi.;Khine Myint.;Naing Naing Mon.;Akihiro Yamamura.;Kazuyoshi Kohu.;Dede Liana Heng.;Sabirah Chen.;Nur Astiana Mawan.;Napat Nuttonmanit.;Ying Li.;Supriya Srivastava.;Shamaine Wei Ting Ho.;Nicole Yee Shin Lee.;Hong Kai Lee.;Makoto Adachi.;Atsushi Tamura.;Jinmiao Chen.;Henry Yang.;Ming Teh.;Jimmy Bok-Yan So.;Wei Peng Yong.;Patrick Tan.;Khay Guan Yeoh.;Linda Shyue Huey Chuang.;Sachiko Tsukita.;Yoshiaki Ito.
来源: Gut. 2021年70卷10期1833-1846页
Tissue stem cells are central regulators of organ homoeostasis. We looked for a protein that is exclusively expressed and functionally involved in stem cell activity in rapidly proliferating isthmus stem cells in the stomach corpus.

1315. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.

作者: Jiandong Zhou.;Xiansong Wang.;Sharen Lee.;William Ka Kei Wu.;Bernard Man Yung Cheung.;Qingpeng Zhang.;Gary Tse.
来源: Gut. 2021年70卷10期2012-2013页

1316. Targeting G protein-coupled receptors for the treatment of chronic pain in the digestive system.

作者: Lena Gottesman-Katz.;Rocco Latorre.;Stephen Vanner.;Brian L Schmidt.;Nigel W Bunnett.
来源: Gut. 2021年70卷5期970-981页
Chronic pain is a hallmark of functional disorders, inflammatory diseases and cancer of the digestive system. The mechanisms that initiate and sustain chronic pain are incompletely understood, and available therapies are inadequate. This review highlights recent advances in the structure and function of pronociceptive and antinociceptive G protein-coupled receptors (GPCRs) that provide insights into the mechanisms and treatment of chronic pain. This knowledge, derived from studies of somatic pain, can guide research into visceral pain. Mediators from injured tissues transiently activate GPCRs at the plasma membrane of neurons, leading to sensitisation of ion channels and acute hyperexcitability and nociception. Sustained agonist release evokes GPCR redistribution to endosomes, where persistent signalling regulates activity of channels and genes that control chronic hyperexcitability and nociception. Endosomally targeted GPCR antagonists provide superior pain relief in preclinical models. Biased agonists stabilise GPCR conformations that favour signalling of beneficial actions at the expense of detrimental side effects. Biased agonists of µ-opioid receptors (MOPrs) can provide analgesia without addiction, respiratory depression and constipation. Opioids that preferentially bind to MOPrs in the acidic microenvironment of diseased tissues produce analgesia without side effects. Allosteric modulators of GPCRs fine-tune actions of endogenous ligands, offering the prospect of refined pain control. GPCR dimers might function as distinct therapeutic targets for nociception. The discovery that GPCRs that control itch also mediate irritant sensation in the colon has revealed new targets. A deeper understanding of GPCR structure and function in different microenvironments offers the potential of developing superior treatments for GI pain.

1317. Development and initial psychometric validation of a patient-reported outcome measure for Crohn's perianal fistula: the Crohn's Anal Fistula Quality of Life (CAF-QoL) scale.

作者: Samuel O Adegbola.;Lesley Dibley.;Kapil Sahnan.;Tiffany Wade.;Azmina Verjee.;Rachel Sawyer.;Sameer Mannick.;Damian McCluskey.;Paul Bassett.;Nuha Yassin.;Janindra Warusavitarne.;Omar Faiz.;Robin Phillips.;Phil J Tozer.;Christine Norton.;Ailsa L Hart.
来源: Gut. 2021年70卷9期1649-1656页
Crohn's perianal fistulas are challenging for patients and clinicians. Many do not respond to available treatments and despite recommendations by a global consensus, there are currently no specific patient-derived quality of life tools to measure response to treatment. We present a new validated patient-reported outcome measure (PROM) for this complicated disease phenotype.

1318. Gut microbiota-derived metabolites as central regulators in metabolic disorders.

作者: Allison Agus.;Karine Clément.;Harry Sokol.
来源: Gut. 2021年70卷6期1174-1182页
Metabolic disorders represent a growing worldwide health challenge due to their dramatically increasing prevalence. The gut microbiota is a crucial actor that can interact with the host by the production of a diverse reservoir of metabolites, from exogenous dietary substrates or endogenous host compounds. Metabolic disorders are associated with alterations in the composition and function of the gut microbiota. Specific classes of microbiota-derived metabolites, notably bile acids, short-chain fatty acids, branched-chain amino acids, trimethylamine N-oxide, tryptophan and indole derivatives, have been implicated in the pathogenesis of metabolic disorders. This review aims to define the key classes of microbiota-derived metabolites that are altered in metabolic diseases and their role in pathogenesis. They represent potential biomarkers for early diagnosis and prognosis as well as promising targets for the development of novel therapeutic tools for metabolic disorders.

1319. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells.

作者: Ting Liu.;Jizhou Tan.;Minhao Wu.;Wenzhe Fan.;Jialiang Wei.;Bowen Zhu.;Jian Guo.;Shutong Wang.;Penghui Zhou.;Hui Zhang.;Liangrong Shi.;Jiaping Li.
来源: Gut. 2021年70卷10期1965-1977页
It remains controversial whether tumour mutational burden (TMB) or neoantigens are prognostic markers in hepatocellular carcinoma (HCC). This study aimed to define the function of TMB or neoantigens in antitumour immunotherapy.

1320. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.

作者: Nannan Sun.;Chuangpeng Shen.;Lei Zhang.;Xiaojie Wu.;Yuanyuan Yu.;Xiaoying Yang.;Chen Yang.;Chong Zhong.;Zhao Gao.;Wei Miao.;Zehong Yang.;Weihang Gao.;Ling Hu.;Kevin Williams.;Changhui Liu.;Yongsheng Chang.;Yong Gao.
来源: Gut. 2021年70卷11期2183-2195页
Impaired hepatic fatty acids oxidation results in lipid accumulation and redox imbalance, promoting the development of fatty liver diseases and insulin resistance. However, the underlying pathogenic mechanism is poorly understood. Krüppel-like factor 16 (KLF16) is a transcription factor that abounds in liver. We explored whether and by what mechanisms KLF16 affects hepatic lipid catabolism to improve hepatosteatosis and insulin resistance.
共有 1921 条符合本次的查询结果, 用时 3.1747309 秒